Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 208-215

  Novello, S ^a   Giaj Levra, M ^a   Vavala T ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Advanced disease; FDG PET; Functional imaging; Non small cell lung cancer; Personalized treatment; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HISTONE DEACETYLASE INHIBITOR; PLACEBO; PLATINUM COMPLEX; PROTEIN KINASE B; WATER O 15;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; GAMMA KNIFE RADIOSURGERY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN EXPRESSION; REPORTER GENE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84864068618     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.09.009     Document Type: Review

References (58)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010 CA. Cancer J Clin 2010, 60. doi:10.3322/caac.20073.
2. Miller A., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
3. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. doi:10.1016/j.ejca.2008.10.026.
4. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad U S A 2000, 97:9226-9233. doi:10.1073/pnas.97.16.9226.
5. Herschman H.R. Molecular imaging: looking at problems, seeing solutions. Science 2003, 302:605-608. doi:10.1126/science.1090585.
6. Massoud T., Gambhir S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Gen Dev 2003, 17:545-580. doi:10.1101/gad.1047403.
7. Alavi A., Kung J.W., Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med 2004, 34:56-69. doi:10.1053/j.semnuclmed.2003.09.007.
8. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer management and oncologic drug development. Clin Cancer Res 2005, 11:2785-2808. doi:10.1158/1078-0432.CCR-04-2626.
9. Torigian D.A., Huang S.S., Houseni M., Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 2007, 57:206-224. doi:10.3322/canjclin.57.4.206.
10. Erasmus J.J., Rohren E., Swisher S.G. Prognosis and revaluation of lung cancer by positron emission tomography imaging. Proc Am Thorac Soc 2009, 6:171-176. doi:10.1513/pats.200806-059LC.
11. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
12. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using 18F-2-fluoro-2deoxy-d-glucose positron emission tomography in patients with locally advanced NSCLC. J Clin Oncol 2005, 23:8362-8370.
13. Weber W.A., Petersen V., Schimdt B., Tyndale-Hines L., Link T., Peschel C. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657. doi:10.1200/JCO.2003.12.004.
14. Weber W.A., Ziegler S., Thodtmann R., Hanauske A.R., Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG-PET. J Nucl Med 1999, 40:1771-1777.
15. Shields A., Grierson J.R., Dohmen B., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 6:1334-1336. doi:10.1038/3337.
16. Czernin J., Wolfang A., Herschman H.R., et al. Molecular imaging in the development of cancer therapeutics. Ann Rev Med 2006, 57:99-118. doi:10.1146/annurev.med.57.080904.190431.
17. Duhaylongsod F.G., Lowe V.j., Patz E.F., Vaughn A.L., Coleman R.E., Wolfe W.G. Lung tumour growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995, 60:1348-1352. doi:10.1016/0003-4975(95)00754-9.
18. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut-1 and Glut-3 in stage I non small cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051. doi:10.1002/(SICI)1097-0142(19970915)80:6<1046:AID-CNCR6>3.0.CO;2-7.
19. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924.
20. Ahuja V., Patz E.F., Coleman R.E., Herndon J., Patz E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma. Cancer 1998, 83:918-924. doi:10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y.
21. Berghmans T., Dusart M., Garcia C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3(1 Jan):6-12. doi:10.1097/JTO.0b0131815e36d6b.
22. Goodgame B., Pillot G.A., Yang Z., et al. Prognostic value of preoperative positron emission tomography in resected stage I non small cell lung cancer. J Thorac Oncol 2008, 3:130-134. doi:10.1097/JTO.0b013e318160c122.
23. Gulenchyn K.Y., Farncombe T., Maziak D.E., et al. Survival of non-small cell lung cancer patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). J Clin Oncol 2010, 28(15s). [suppl; abstr 7076].
24. Jansson T., Westlin J.E., Ahlstrom H., Lilja A., Langstrom B., Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 1995, 13:1470-1477.
25. Findlay M., Young H., Cunningham D., et al. Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996, 14:700-708.
26. Haberkorn U., Morr I., Oberdorfer F., et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med 1994, 35:1842-1850.
27. Higashi K., Anaira C., Wahl R.L. In vitro assessment of 2-fluoro-2-deoxy-d-glucose, L methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993, 34:773-779.
28. Rozental J.M., Levine R.L., Nickles R.J., Dobkin J.A. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989, 46:1302-1307.
29. Maruyama I., Sadato N., Waki A., et al. Hyperacute changes in glucose metabolism of brain tumours after stereotactic radiosurgery: a PET study. J Clin Med 1999, 40:1085-1090.
30. Castellucci P., Zinzani P., Nanni C., et al. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm 2004, 19:606-612. doi:10.1089/cbr.2004.19.606.
31. Plowman P.N. Sterotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg 1999, 13:256-264. doi:10.1080/02688699943655.
32. Young H., Baum R., Cemerius U., et al. Measurement of clinical and subclinical tumour response using f-18-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999, 35:1773-1782. doi:10.1016/S0959-8049(99)00229-4.
33. Shankar L.K., Hoffman J.M.S., Bacharach M.M., et al. Consensus recommendations for the use 18F-FDG-PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Clin Med 2006, 47(6).
34. Minn H., Zasadny K.R., Quint L.E., Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2[F-18-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 1995, 196:167-173.
35. Ichiya Y., Kuwabara Y., Sasaki M., et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996, 10:193-200. doi:10.1007/BF03165392.
36. Lee H.Y., Lee H.J., Kim J.T., et al. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in NSCLC. J Thorac Oncol 2010, 5/4:497-502. 10.1097/JTO.0b013e3181d2efe7.
37. Nahmias C., Hanna W.T., Wahl L.M., Long M.J., Hubner K.F., Townsend D.W. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007, 48:744-751. doi:10.2967/jnumed.106.038513.
38. Poettgen C., Theegarten D., Eberhardt W., et al. Correlation of PET/CT findings and histopathology after neo-adjuvant therapy in NSCLC. Oncology 2007, 73:316-323. doi:10.1159/000134474.
39. Rebollo-Aguirre A., Ramos-Font C., Portero R.V., Cook G., Llamas E.J.M., Tabares A.R. Is FDG-PET suitable for evaluating neo-adjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol 2010, 101(6):486-494. doi:10.1002/jso.21525.
40. de Geus-oei L., Oyen W.J.G., Visser E.P., et al. Chemotherapy response evaluation with 18FFDG PET in patients with NSCLC. J Nucl Med 2007, 48(10):1592-1597. doi:10.2967/jnumed.107.043414.
41. Shepherd F., Pereira J., Ciuleanu T., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure first line or second line chemotherapy. A national Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004, 22:A-7022.
42. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496 Oct 29-Nov 4):1527-1537. doi:10.1016/S0140-6736(05)67625-8.
43. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365. doi:10.1038/35077225.
44. Margaret A., Lawlor, Alessi D.R. PKB/Akt a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 2001, 114:2903-2910.
45. Stroobants S., Goeminne J., Seegers M., et al. 18 FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020. doi:10.1016/S0959-8049(03)00073-X.
46. Whiteman E.L., Cho H., Birnabaum M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002, 13:444-451. doi:10.1016/S1043-2760(02)00662-8.
47. Majumder P.K., Febbo P.G., Bikoff R., et al. MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Nat Med 2004, (10):594-601. doi:10.1038/nm1052.
48. Elstrom R.L., Bauer D.E., Buzzai M., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899. doi:10.1158/0008-5472.CAN-03-2904.
49. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003, 9:2316-2326.
50. Su H., Bodenstein C., Dumont R.A., et al. Monitoring tumour glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006, 12:5659-5667. doi:10.1158/1078-0432.CCR-06-0368.
51. Cullinane C., Dorow D.S., Kansara M., et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005, 65:9633-9636. doi:10.1158/0008-5472.CAN-05-2285.
52. Mileshkin L., Hughes B.G.M., Mitchell P., et al. Changes in FDG and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib. J Clin Oncol 2010, 28(15s). [suppl; abstr 7567].
53. Choi C., Shin K., Lee D., et al. The usefulness of 18f-fluorothymidine (FLT) and 18f-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer. J Clin Oncol 2010, 28(15s). [suppl; abstr 7545].
54. Nogovóa Lucia, Boellaard Ronald, Kobe3 Carsten, et al. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor Everolimus. J Nucl Med 2009, 50(November (11)):1815-1819. doi:10.2967/jnumed.109.065367.
55. Chen W., Delaloye, Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with 18Fluorothimydine Positron Emission Tomography: a pilot study. J Clin Oncol 2007, 25:4714-4721. doi:10.1200/JCO.5825.200610.
56. Groves A.M., Win T., Ben Haim S., Eli P.J. Non-18FFDG PET in clinical oncology. Lancet 2007, 8:822-830. doi:10.1016/S1470-2045(07)70274-7.
57. Van Loon J., Jansenn M.H.M., Ollers M., et al. PET imaging using 18FHX4 a phase I trial. Eur J Nucl Med Molec Imaging 2010, doi:10.1007/s00259-010-1437-x.
58. Doubrovin M., Ponomarev V., Beresten T., et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. PNAS 2001, 98-9300-5. doi:10.1073/pnas.161091198.